First Page | Document Content | |
---|---|---|
Date: 2017-10-30 18:54:27 | Visterra to Present New Preclinical Results on VIS649, its Antibody for the Treatment of IgA Nephropathy, at the American Society of Nephrology Kidney Week Conference - VIS649 Reduced Serum IgA, with Favorable Safety ProAdd to Reading ListSource URL: visterrainc.comDownload Document from Source WebsiteFile Size: 119,00 KBShare Document on Facebook |